Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lixadesiran
- Development stage
- Unknown
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Topical, Intratumoral, Subcutaneous
01
Overview
Lixadesiran is a small interfering RNA (siRNA) therapeutic under development for the treatment of cutaneous squamous cell carcinoma (cSCC) and other skin-related conditions. It acts by targeting and inhibiting cyclooxygenase-2 (COX-2), an enzyme involved in inflammation and tumorigenesis, as well as transforming growth factor beta 1 (TGF-β1), which plays a role in fibrosis and cancer progression. Lixadesiran is administered via intradermal injection, topical cream, intra-tumoral, or subcutaneous routes. The drug is being developed using Sirnaomics' proprietary PNP platform and has reached Phase II clinical trials for cSCC. Other indications explored include basal cell carcinoma, primary sclerosing cholangitis, keloid scar healing, hypertrophic scars, abdominal obesity, pulmonary fibrosis, kidney fibrosis, wounds, pancreatic cancer, non-alcoholic steatohepatitis (NASH), cholangiocarcinoma, hepatocellular carcinoma and bladder cancer[2][4][7].
- Other names
- lixadesiran sodium
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on lixadesiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lixadesiran.